Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: WDR12 (ImmuneEditome ID:55759)

1. Gene summary of enriched editing regions for WDR12

Gene summary

Gene information	Gene symbol	WDR12
	Gene ID	55759
	GeneSynonyms	YTM1
	GeneCytomap	2q33.2
	GeneType	protein-coding
	GeneDescription	ribosome biogenesis protein WDR12\|WD repeat-containing protein 12
	GeneModificationdate	20230329
	UniprotID	Q9GZL7;Q53T99
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr2:202875407-202877696:-	ENST00000261015.4	ENSG00000138442.8	WDR12	UTR3	AluSp,AluJr,AluJb,AluSz6,(TA)n	chr2:202875407-202877696:-.alignment
chr2:202879017-202880544:-	ENST00000261015.4	ENSG00000138442.8	WDR12	UTR3	AluSx,AluSx3,AluSx1	chr2:202879017-202880544:-.alignment
chr2:202886297-202887141:-	ENST00000475611.1	ENSG00000138442.8	WDR12	ncRNA_intronic	AluSp,AluSx,AluJb,L1M5,MER58C	chr2:202886297-202887141:-.alignment
chr2:202886297-202887141:-	ENST00000477727.4	ENSG00000138442.8	WDR12	ncRNA_intronic	AluSp,AluSx,AluJb,L1M5,MER58C	chr2:202886297-202887141:-.alignment

Top

2. Tumor-specific enriched editing regions for WDR12

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr2:202875407-202877696:-	KIRC	Path	EER	4.0434e-02	4.2540e-03	0.1660
ENSG00000138442.8,WDR12	KIRC	Path	EAG	3.2848e-03	6.6184e-04	0.1685
chr2:202879017-202880544:-	KIRP	Cli	EER	2.3222e-02	4.4914e-03	-0.2422

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr2:202879017-202880544:-	BRCA	EER	2.6998e-02	9.6046e-03	2.0422e+01

Top

3. Enriched editing regions and immune related genes for WDR12

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr2:202879017-202880544:-

COAD

EER

ENSG00000169826,CSGALNACT2

0.3081

1.1768e-03

1.3721e-09

0.4118

Neutrophils

GSVA_HALLMARK_DNA_REPAIR

chr2:202879017-202880544:-

ESCA

EER

ENSG00000129317,PUS7L

-0.4273

1.6887e-04

2.9393e-07

-0.4028

T_cells_CD4_memory_resting

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr2:202879017-202880544:-

ESCA

EER

ENSG00000234975,FTH1P2

0.3653

2.6087e-03

2.5205e-07

0.4049

Macrophages_M1

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results

Top

4. Enriched editing regions and immune related splicing for WDR12

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000138442.8,WDR12

ESCA

EAG

MEX

ENSG00000072609.13

chr12

132861546:132861634:132862332:132862425:132869618:132869831:132870723:132870783

0.3355

1.3736e-02

6.6042e-07

0.4154

ACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

ENSG00000138442.8,WDR12

ESCA

EAG

ENSG00000043514.11

chr1

39850122:39850261:39852730:39852876:39853969:39854068

-0.4011

1.6534e-03

5.7608e-09

-0.4560

ACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZNF184

Macrophages_M2

GSVA_HALLMARK_G2M_CHECKPOINT

ENSG00000138442.8,WDR12

ESCA

EAG

MEX

ENSG00000072609.13

chr12

132861546:132861634:132862332:132862425:132869618:132869783:132870723:132870783

0.3348

1.4121e-02

6.6620e-07

0.4153

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

chr2:202879017-202880544:-

ESCA

EER

ENSG00000129696.8

chr8

33498953:33499277:33500327:33500490

-0.3682

1.0872e-02

2.2882e-07

-0.4062

T_cells_CD8

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000138442.8,WDR12

ESCA

EAG

ENSG00000119640.4

chr14

75053242:75053659:75063953:75064007:75063469:75064007

0.2769

4.1119e-02

1.6284e-07

0.4094

ACIN1;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

T_cells_gamma_delta

GSVA_HALLMARK_PEROXISOME

ENSG00000138442.8,WDR12

ESCA

EAG

ENSG00000119640.4

chr14

75053242:75053659:75063469:75063561:75063953:75064007

-0.2753

4.3768e-02

1.9603e-07

-0.4070

T_cells_gamma_delta

GSVA_HALLMARK_PEROXISOME

chr2:202879017-202880544:-

ESCA

EER

ENSG00000043514.11

chr1

39850122:39850261:39852730:39852876:39853969:39854068

-0.3902

2.7217e-03

1.8456e-09

-0.4718

Macrophages_M2

GSVA_HALLMARK_G2M_CHECKPOINT

chr2:202875407-202877696:-

ESCA

EER

ENSG00000116786.7

chr1

15732349:15732529:15732614:15732728

-0.2159

3.9858e-02

9.8829e-07

-0.4095

Mast_cells_activated

ENSG00000138442.8,WDR12

KIRP

EAG

ENSG00000106344.4

chr7

128330818:128330928:128324558:128324694:128324558:128325891

0.2135

3.0026e-02

3.1874e-13

0.4898

ACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

NK_cells_resting

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

ENSG00000138442.8,WDR12

KIRP

EAG

ENSG00000106344.4

chr7

128324607:128324694:128325817:128325891:128330818:128330928

-0.2241

1.2874e-02

2.9603e-13

-0.5030

NK_cells_resting

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results

Top

5. Enriched editing regions and immune infiltration for WDR12

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000138442.8,WDR12	ACC	EAG	Mast_cells_resting	2.0659e-02	0.3742
chr2:202875407-202877696:-	BLCA	EER	B_cells_memory	1.8926e-02	-0.2636
chr2:202879017-202880544:-	BLCA	EER	Mast_cells_activated	9.1688e-03	0.1959
ENSG00000138442.8,WDR12	BLCA	EAG	NK_cells_activated	1.2873e-02	-0.1811
chr2:202879017-202880544:-	BRCA	EER	Dendritic_cells_resting	2.6122e-03	0.1088
ENSG00000138442.8,WDR12	BRCA	EAG	Dendritic_cells_resting	6.4384e-03	0.0945
chr2:202879017-202880544:-	CESC	EER	Macrophages_M1	2.3273e-02	0.1846
ENSG00000138442.8,WDR12	CESC	EAG	Macrophages_M1	1.2760e-02	0.1912
chr2:202879017-202880544:-	CHOL	EER	T_cells_gamma_delta	4.4261e-02	-0.4056
chr2:202879017-202880544:-	COAD	EER	Macrophages_M2	7.2791e-03	0.1892
ENSG00000138442.8,WDR12	COAD	EAG	Macrophages_M2	8.8673e-04	0.2187
ENSG00000138442.8,WDR12	DLBC	EAG	T_cells_gamma_delta	7.0134e-03	0.5697
chr2:202875407-202877696:-	ESCA	EER	Monocytes	2.4865e-02	-0.1931
chr2:202879017-202880544:-	ESCA	EER	T_cells_CD4_memory_resting	9.9558e-04	-0.2653
ENSG00000138442.8,WDR12	ESCA	EAG	Macrophages_M2	5.9711e-03	0.2213
chr2:202875407-202877696:-	GBM	EER	Plasma_cells	4.7267e-03	0.2640
chr2:202879017-202880544:-	GBM	EER	NK_cells_activated	3.8932e-02	-0.1711
ENSG00000138442.8,WDR12	GBM	EAG	T_cells_follicular_helper	1.3338e-02	-0.2037
chr2:202875407-202877696:-	HNSC	EER	Monocytes	1.1939e-02	0.2076
chr2:202879017-202880544:-	HNSC	EER	NK_cells_activated	3.0094e-02	0.1292
ENSG00000138442.8,WDR12	HNSC	EAG	NK_cells_activated	3.0769e-02	0.1258
chr2:202879017-202880544:-	KICH	EER	Macrophages_M0	3.0747e-03	0.5677
ENSG00000138442.8,WDR12	KICH	EAG	Macrophages_M0	2.0177e-02	0.4445
chr2:202875407-202877696:-	KIRC	EER	Plasma_cells	1.2228e-02	0.1650
ENSG00000138442.8,WDR12	KIRC	EAG	Macrophages_M0	3.2806e-03	0.1678
chr2:202875407-202877696:-	KIRP	EER	T_cells_CD4_memory_activated	3.7011e-05	0.3322
chr2:202879017-202880544:-	KIRP	EER	Macrophages_M2	1.3028e-02	0.1808
ENSG00000138442.8,WDR12	KIRP	EAG	NK_cells_activated	3.2556e-02	-0.1472
chr2:202886297-202887141:-	LAML	EER	Mast_cells_activated	1.2335e-02	0.5239
ENSG00000138442.8,WDR12	LAML	EAG	NK_cells_resting	2.6771e-03	0.3294
chr2:202875407-202877696:-	LGG	EER	Eosinophils	6.4649e-03	0.1302
chr2:202879017-202880544:-	LGG	EER	Dendritic_cells_resting	4.5392e-03	0.1330
ENSG00000138442.8,WDR12	LGG	EAG	Eosinophils	3.9547e-03	0.1297
ENSG00000138442.8,WDR12	LIHC	EAG	T_cells_CD8	1.4316e-02	0.1743
chr2:202879017-202880544:-	LUAD	EER	Neutrophils	4.2988e-02	-0.1360
ENSG00000138442.8,WDR12	LUAD	EAG	Neutrophils	2.8243e-02	-0.1393
chr2:202875407-202877696:-	LUSC	EER	Macrophages_M0	7.2723e-03	-0.2000
chr2:202879017-202880544:-	LUSC	EER	Dendritic_cells_activated	1.1403e-02	0.1524
ENSG00000138442.8,WDR12	LUSC	EAG	Neutrophils	1.2362e-02	0.1450
chr2:202875407-202877696:-	MESO	EER	B_cells_naive	2.3187e-02	-0.4524
chr2:202879017-202880544:-	MESO	EER	T_cells_CD4_memory_activated	7.3778e-03	-0.3985
ENSG00000138442.8,WDR12	MESO	EAG	T_cells_CD4_memory_activated	2.2544e-02	-0.3287
chr2:202875407-202877696:-	OV	EER	T_cells_CD8	1.2087e-02	0.1847
chr2:202879017-202880544:-	OV	EER	T_cells_CD8	1.1684e-02	0.1571
ENSG00000138442.8,WDR12	OV	EAG	T_cells_CD8	1.7072e-03	0.1940
chr2:202875407-202877696:-	PAAD	EER	B_cells_memory	1.0303e-02	0.4405
ENSG00000138442.8,WDR12	PAAD	EAG	Dendritic_cells_activated	4.8545e-02	-0.2496
chr2:202875407-202877696:-	PCPG	EER	T_cells_CD4_memory_resting	5.4927e-04	-0.3024
ENSG00000138442.8,WDR12	PCPG	EAG	T_cells_regulatory_(Tregs)	4.0460e-02	0.1627
chr2:202875407-202877696:-	PRAD	EER	Plasma_cells	1.7919e-02	-0.1581
ENSG00000138442.8,WDR12	PRAD	EAG	Plasma_cells	2.9363e-02	-0.1201
chr2:202875407-202877696:-	READ	EER	NK_cells_resting	1.6075e-02	0.3096
chr2:202879017-202880544:-	READ	EER	T_cells_regulatory_(Tregs)	2.5776e-03	0.3454
chr2:202875407-202877696:-	SARC	EER	Eosinophils	2.9517e-02	0.2322
chr2:202879017-202880544:-	SARC	EER	T_cells_CD4_memory_resting	1.0376e-02	-0.2341
ENSG00000138442.8,WDR12	SARC	EAG	Eosinophils	1.1161e-02	0.2116
chr2:202875407-202877696:-	SKCM	EER	T_cells_CD8	1.4186e-04	0.2334
chr2:202879017-202880544:-	SKCM	EER	Plasma_cells	7.6546e-03	0.1366
ENSG00000138442.8,WDR12	SKCM	EAG	Plasma_cells	4.6062e-04	0.1772
chr2:202875407-202877696:-	STAD	EER	Macrophages_M1	2.9146e-02	0.1366
chr2:202879017-202880544:-	STAD	EER	T_cells_CD8	1.7996e-03	0.1813
ENSG00000138442.8,WDR12	STAD	EAG	Macrophages_M1	8.2895e-03	0.1495
chr2:202875407-202877696:-	TGCT	EER	T_cells_CD4_memory_activated	3.0504e-03	0.3762
chr2:202879017-202880544:-	TGCT	EER	Neutrophils	6.3958e-03	0.2380
ENSG00000138442.8,WDR12	TGCT	EAG	Neutrophils	2.4620e-03	0.2624
chr2:202875407-202877696:-	THCA	EER	Eosinophils	2.6563e-02	0.1653
chr2:202879017-202880544:-	THCA	EER	Macrophages_M0	1.2068e-03	0.1799
ENSG00000138442.8,WDR12	THCA	EAG	NK_cells_activated	6.3498e-04	-0.1800
chr2:202879017-202880544:-	THYM	EER	B_cells_memory	2.5972e-02	0.2521
ENSG00000138442.8,WDR12	THYM	EAG	T_cells_CD4_memory_activated	1.1988e-02	0.2714
chr2:202875407-202877696:-	UCEC	EER	Mast_cells_resting	3.6400e-02	0.2685
chr2:202879017-202880544:-	UCEC	EER	Monocytes	4.5650e-02	0.1791
chr2:202879017-202880544:-	UCS	EER	Neutrophils	1.1501e-02	0.3695
ENSG00000138442.8,WDR12	UCS	EAG	Neutrophils	4.9385e-02	0.2823
ENSG00000138442.8,WDR12	UVM	EAG	T_cells_follicular_helper	3.9979e-02	-0.3074

Top

6. Enriched editing regions and immune gene sets for WDR12

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000138442.8,WDR12	SKCM	EAG	1.3387e-02	-0.1256	2.4496e-02	-0.1143	3.7903e-02	-0.1056	1.2787e-02	0.1265

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000138442.8,WDR12	ACC	GSVA_HALLMARK_PEROXISOME	EAG	6.5185e-05	-0.6014
chr2:202875407-202877696:-	BLCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	9.7076e-03	0.2893
ENSG00000138442.8,WDR12	BLCA	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	9.9097e-04	0.2383
chr2:202879017-202880544:-	BLCA	GSVA_HALLMARK_UV_RESPONSE_UP	EER	1.6440e-03	0.2356
ENSG00000138442.8,WDR12	BRCA	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.5042e-03	0.1099
chr2:202879017-202880544:-	BRCA	GSVA_HALLMARK_APOPTOSIS	EER	5.2257e-04	0.1252
chr2:202875407-202877696:-	BRCA	GSVA_HALLMARK_MYOGENESIS	EER	1.5228e-03	0.1302
ENSG00000138442.8,WDR12	CESC	GSVA_HALLMARK_SPERMATOGENESIS	EAG	9.3007e-03	-0.1995
chr2:202875407-202877696:-	CESC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	3.7354e-02	0.2347
chr2:202879017-202880544:-	CESC	GSVA_HALLMARK_SPERMATOGENESIS	EER	1.9853e-03	-0.2497
chr2:202875407-202877696:-	CHOL	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	2.9211e-02	-0.4650
ENSG00000138442.8,WDR12	CHOL	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	3.6354e-02	0.4045
ENSG00000138442.8,WDR12	COAD	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	2.0258e-06	0.3086
chr2:202879017-202880544:-	COAD	GSVA_HALLMARK_COMPLEMENT	EER	5.6917e-05	0.2806
chr2:202875407-202877696:-	COAD	GSVA_HALLMARK_NOTCH_SIGNALING	EER	2.0836e-03	0.2338
ENSG00000138442.8,WDR12	DLBC	GSVA_HALLMARK_COAGULATION	EAG	1.2865e-03	0.6545
ENSG00000138442.8,WDR12	ESCA	GSVA_HALLMARK_PEROXISOME	EAG	3.2971e-03	-0.2361
chr2:202879017-202880544:-	ESCA	GSVA_HALLMARK_HYPOXIA	EER	4.3061e-03	0.2311
chr2:202875407-202877696:-	GBM	GSVA_HALLMARK_MTORC1_SIGNALING	EER	2.6396e-03	0.2803
ENSG00000138442.8,WDR12	GBM	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	1.2589e-03	0.2635
chr2:202879017-202880544:-	GBM	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	1.2629e-03	0.2643
ENSG00000138442.8,WDR12	HNSC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	2.4701e-02	-0.1308
chr2:202879017-202880544:-	HNSC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.0042e-02	-0.1531
chr2:202875407-202877696:-	HNSC	GSVA_HALLMARK_APICAL_JUNCTION	EER	2.6378e-03	0.2471
chr2:202875407-202877696:-	KIRC	GSVA_HALLMARK_G2M_CHECKPOINT	EER	4.7229e-02	0.1310
ENSG00000138442.8,WDR12	KIRC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	3.9010e-02	-0.1183
chr2:202879017-202880544:-	KIRP	GSVA_HALLMARK_KRAS_SIGNALING_UP	EER	8.0928e-03	0.1926
ENSG00000138442.8,WDR12	LAML	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	6.5297e-03	-0.2999
chr2:202886297-202887141:-	LAML	GSVA_HALLMARK_E2F_TARGETS	EER	1.9114e-02	-0.4952
chr2:202875407-202877696:-	LGG	GSVA_HALLMARK_MYC_TARGETS_V2	EER	2.7912e-08	-0.2621
chr2:202879017-202880544:-	LGG	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.2533e-05	-0.2034
ENSG00000138442.8,WDR12	LGG	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	1.3847e-10	-0.2841
ENSG00000138442.8,WDR12	LIHC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	3.0598e-02	0.1541
chr2:202875407-202877696:-	LIHC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	2.9064e-02	0.1930
ENSG00000138442.8,WDR12	LUAD	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	2.6234e-02	0.1412
chr2:202879017-202880544:-	LUAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	1.4260e-02	0.1643
chr2:202875407-202877696:-	LUSC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.0566e-02	-0.1907
ENSG00000138442.8,WDR12	LUSC	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	5.2154e-03	-0.1617
chr2:202875407-202877696:-	MESO	GSVA_HALLMARK_DNA_REPAIR	EER	1.1766e-02	0.4956
ENSG00000138442.8,WDR12	MESO	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	2.7323e-02	-0.3186
ENSG00000138442.8,WDR12	OV	GSVA_HALLMARK_COMPLEMENT	EAG	2.4208e-06	0.2881
chr2:202875407-202877696:-	OV	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	5.5063e-05	0.2928
chr2:202879017-202880544:-	OV	GSVA_HALLMARK_COAGULATION	EER	4.3895e-04	0.2177
ENSG00000138442.8,WDR12	PAAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	4.7282e-02	-0.2509
chr2:202879017-202880544:-	PAAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	3.9970e-02	-0.2682
chr2:202875407-202877696:-	PAAD	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	2.1626e-02	-0.3985
chr2:202875407-202877696:-	PCPG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.3003e-02	0.2199
ENSG00000138442.8,WDR12	PCPG	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	8.7772e-03	-0.2072
chr2:202879017-202880544:-	PCPG	GSVA_HALLMARK_MYC_TARGETS_V1	EER	1.6645e-03	-0.2538
ENSG00000138442.8,WDR12	PRAD	GSVA_HALLMARK_ANGIOGENESIS	EAG	3.5521e-04	0.1957
chr2:202879017-202880544:-	PRAD	GSVA_HALLMARK_ANGIOGENESIS	EER	3.0103e-02	0.1306
chr2:202875407-202877696:-	PRAD	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.2622e-02	0.1664
ENSG00000138442.8,WDR12	READ	GSVA_HALLMARK_P53_PATHWAY	EAG	4.4291e-02	0.2241
chr2:202875407-202877696:-	READ	GSVA_HALLMARK_UV_RESPONSE_UP	EER	2.2390e-02	0.2944
chr2:202875407-202877696:-	SARC	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	1.2064e-02	0.2666
chr2:202879017-202880544:-	SARC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.8790e-03	0.2628
ENSG00000138442.8,WDR12	SARC	GSVA_HALLMARK_MYOGENESIS	EAG	7.5018e-03	0.2227
ENSG00000138442.8,WDR12	SKCM	GSVA_HALLMARK_COMPLEMENT	EAG	4.4118e-05	0.2061
chr2:202875407-202877696:-	SKCM	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.5141e-03	0.1954
chr2:202879017-202880544:-	SKCM	GSVA_HALLMARK_COMPLEMENT	EER	5.1115e-04	0.1774
chr2:202875407-202877696:-	STAD	GSVA_HALLMARK_COAGULATION	EER	2.3868e-03	0.1894
chr2:202879017-202880544:-	STAD	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	6.6622e-06	0.2593
ENSG00000138442.8,WDR12	STAD	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	3.1317e-04	0.2031
chr2:202879017-202880544:-	TGCT	GSVA_HALLMARK_APICAL_SURFACE	EER	8.9016e-03	0.2286
ENSG00000138442.8,WDR12	TGCT	GSVA_HALLMARK_APICAL_SURFACE	EAG	2.2083e-02	0.1999
ENSG00000138442.8,WDR12	THCA	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	4.2026e-02	-0.1077
chr2:202875407-202877696:-	THCA	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	2.3630e-02	-0.1686
chr2:202879017-202880544:-	THYM	GSVA_HALLMARK_PROTEIN_SECRETION	EER	9.5815e-04	-0.3667
ENSG00000138442.8,WDR12	THYM	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	9.4097e-03	-0.2802
ENSG00000138442.8,WDR12	UCEC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.0314e-02	0.2201
chr2:202879017-202880544:-	UCEC	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	1.5695e-02	0.2157
chr2:202875407-202877696:-	UCEC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	7.4107e-03	0.3396
ENSG00000138442.8,WDR12	UCS	GSVA_HALLMARK_MYOGENESIS	EAG	3.5217e-02	-0.3016
chr2:202879017-202880544:-	UCS	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.3148e-02	-0.3630
chr2:202879017-202880544:-	UVM	GSVA_HALLMARK_HEME_METABOLISM	EER	3.3019e-02	0.3184
ENSG00000138442.8,WDR12	UVM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	3.2129e-02	0.3200
chr2:202875407-202877696:-	UVM	GSVA_HALLMARK_DNA_REPAIR	EER	4.3082e-05	-0.7031

Top

7. Enriched editing regions and drugs for WDR12

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000138442.8,WDR12	ACC	BMS.708163	EAG	1.3368e-03	0.5016
chr2:202879017-202880544:-	BLCA	GW.441756	EER	1.4295e-03	0.2386
chr2:202875407-202877696:-	BLCA	Elesclomol	EER	3.6974e-03	0.3230
ENSG00000138442.8,WDR12	BLCA	Elesclomol	EAG	5.8807e-04	0.2484
ENSG00000138442.8,WDR12	BRCA	AZD6482	EAG	1.1748e-03	-0.1124
chr2:202879017-202880544:-	BRCA	ABT.263	EER	1.9221e-02	0.0849
chr2:202875407-202877696:-	BRCA	Methotrexate	EER	3.0296e-02	0.0892
chr2:202875407-202877696:-	CESC	GW.441756	EER	4.2023e-02	-0.2294
chr2:202879017-202880544:-	CESC	BIBW2992	EER	1.4747e-02	-0.1988
ENSG00000138442.8,WDR12	CESC	BIBW2992	EAG	4.3159e-03	-0.2191
chr2:202879017-202880544:-	CHOL	BI.D1870	EER	1.4650e-03	0.6016
ENSG00000138442.8,WDR12	CHOL	BI.D1870	EAG	3.8756e-02	0.3999
chr2:202875407-202877696:-	CHOL	GDC.0449	EER	2.1741e-02	-0.4863
ENSG00000138442.8,WDR12	COAD	AP.24534	EAG	5.9072e-05	-0.2628
chr2:202879017-202880544:-	COAD	AP.24534	EER	7.3405e-05	-0.2766
chr2:202875407-202877696:-	COAD	Bicalutamide	EER	2.6328e-02	-0.1699
ENSG00000138442.8,WDR12	DLBC	AZD.2281	EAG	7.4555e-06	-0.8131
chr2:202879017-202880544:-	ESCA	CGP.60474	EER	7.9968e-06	-0.3545
chr2:202875407-202877696:-	ESCA	Methotrexate	EER	1.7341e-02	0.2045
ENSG00000138442.8,WDR12	ESCA	GNF.2	EAG	2.5162e-04	-0.2919
chr2:202875407-202877696:-	GBM	Bosutinib	EER	1.7024e-04	0.3465
chr2:202879017-202880544:-	GBM	Epothilone.B	EER	1.5696e-03	0.2594
ENSG00000138442.8,WDR12	GBM	GSK.650394	EAG	3.0134e-03	0.2431
chr2:202879017-202880544:-	HNSC	Erlotinib	EER	2.5176e-05	-0.2489
chr2:202875407-202877696:-	HNSC	ATRA	EER	4.1574e-03	0.2359
ENSG00000138442.8,WDR12	HNSC	Erlotinib	EAG	1.2137e-05	-0.2525
chr2:202875407-202877696:-	KIRC	AZD7762	EER	9.8177e-03	-0.1700
chr2:202879017-202880544:-	KIRC	AZD.2281	EER	3.2426e-03	-0.1756
ENSG00000138442.8,WDR12	KIRC	AZD.2281	EAG	1.2834e-03	-0.1838
chr2:202879017-202880544:-	KIRP	ATRA	EER	1.9574e-02	-0.1702
ENSG00000138442.8,WDR12	KIRP	ATRA	EAG	1.3742e-02	-0.1694
chr2:202875407-202877696:-	KIRP	Bexarotene	EER	3.3645e-02	0.1748
ENSG00000138442.8,WDR12	LAML	EHT.1864	EAG	1.3989e-02	0.2721
chr2:202886297-202887141:-	LAML	A.770041	EER	1.1906e-02	-0.5261
chr2:202879017-202880544:-	LGG	AZD8055	EER	5.7482e-08	0.2513
chr2:202875407-202877696:-	LGG	Epothilone.B	EER	1.1692e-07	0.2504
ENSG00000138442.8,WDR12	LGG	Axitinib	EAG	5.4352e-13	0.3176
chr2:202875407-202877696:-	LIHC	Bortezomib	EER	3.6744e-03	0.2550
ENSG00000138442.8,WDR12	LIHC	Erlotinib	EAG	2.2471e-02	-0.1730
chr2:202879017-202880544:-	LIHC	Erlotinib	EER	1.2627e-02	-0.2081
ENSG00000138442.8,WDR12	LUAD	AZD6482	EAG	1.2025e-03	0.2045
chr2:202879017-202880544:-	LUAD	JNK.9L	EER	1.9907e-03	0.2064
chr2:202875407-202877696:-	LUSC	DMOG	EER	1.3900e-02	-0.1836
ENSG00000138442.8,WDR12	LUSC	GW.441756	EAG	2.7911e-02	0.1276
chr2:202879017-202880544:-	LUSC	GW.441756	EER	4.8928e-02	0.1189
chr2:202875407-202877696:-	MESO	BMS.509744	EER	6.3114e-04	-0.6361
ENSG00000138442.8,WDR12	MESO	Cyclopamine	EAG	1.2901e-04	-0.5247
chr2:202879017-202880544:-	MESO	GDC.0449	EER	3.9327e-02	-0.3118
ENSG00000138442.8,WDR12	OV	GNF.2	EAG	1.5977e-03	-0.1952
chr2:202879017-202880544:-	OV	GNF.2	EER	8.8024e-04	-0.2063
chr2:202875407-202877696:-	OV	AG.014699	EER	1.5237e-02	0.1787
ENSG00000138442.8,WDR12	PAAD	JNK.9L	EAG	2.3609e-02	0.2849
ENSG00000138442.8,WDR12	PCPG	Embelin	EAG	5.8077e-05	0.3132
chr2:202875407-202877696:-	PCPG	GSK269962A	EER	3.5638e-02	0.1866
chr2:202879017-202880544:-	PCPG	Embelin	EER	3.9970e-05	0.3277
chr2:202879017-202880544:-	PRAD	Dasatinib	EER	4.3192e-03	-0.1719
chr2:202875407-202877696:-	PRAD	CCT007093	EER	8.0740e-03	-0.1766
ENSG00000138442.8,WDR12	PRAD	GW.441756	EAG	1.4417e-03	0.1750
chr2:202879017-202880544:-	READ	BMS.754807	EER	3.2800e-02	-0.2485
ENSG00000138442.8,WDR12	READ	AZD6244	EAG	3.0476e-02	-0.2421
chr2:202875407-202877696:-	READ	CI.1040	EER	3.9197e-02	-0.2670
chr2:202875407-202877696:-	SARC	JNJ.26854165	EER	5.2990e-03	-0.2948
chr2:202879017-202880544:-	SARC	A.770041	EER	3.5176e-06	-0.4106
ENSG00000138442.8,WDR12	SARC	A.770041	EAG	1.1960e-03	-0.2683
chr2:202875407-202877696:-	SKCM	Methotrexate	EER	2.9368e-02	-0.1362
ENSG00000138442.8,WDR12	SKCM	CGP.60474	EAG	2.0833e-04	-0.1875
chr2:202879017-202880544:-	SKCM	CGP.60474	EER	2.3695e-04	-0.1875
ENSG00000138442.8,WDR12	STAD	Bortezomib	EAG	5.8879e-04	-0.1938
chr2:202879017-202880544:-	STAD	AZ628	EER	5.0296e-04	-0.2017
chr2:202875407-202877696:-	STAD	BIBW2992	EER	1.0887e-02	0.1602
chr2:202875407-202877696:-	TGCT	AZD8055	EER	1.8579e-02	-0.3031
ENSG00000138442.8,WDR12	TGCT	Dasatinib	EAG	4.5699e-03	-0.2463
chr2:202879017-202880544:-	TGCT	Dasatinib	EER	1.6695e-03	-0.2731
chr2:202875407-202877696:-	THCA	Gefitinib	EER	2.2571e-03	-0.2263
chr2:202879017-202880544:-	THCA	Dasatinib	EER	1.2827e-02	-0.1388
ENSG00000138442.8,WDR12	THCA	BAY.61.3606	EAG	8.4941e-03	0.1391
ENSG00000138442.8,WDR12	THYM	AZD6244	EAG	2.5013e-07	-0.5250
chr2:202879017-202880544:-	THYM	Embelin	EER	5.0140e-07	0.5332
chr2:202879017-202880544:-	UCEC	Axitinib	EER	5.4120e-03	0.2474
ENSG00000138442.8,WDR12	UCEC	Axitinib	EAG	7.6743e-03	0.2285
chr2:202875407-202877696:-	UCEC	LFM.A13	EER	3.4483e-03	-0.3688
chr2:202879017-202880544:-	UCS	AKT.inhibitor.VIII	EER	4.5530e-03	-0.4110
ENSG00000138442.8,WDR12	UCS	AKT.inhibitor.VIII	EAG	4.5630e-03	-0.3985
chr2:202875407-202877696:-	UVM	A.443654	EER	2.6309e-03	0.5555

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType